I am a
Home I AM A Search Login

Papers of the Week

2021 May

Anatol J Cardiol



Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients.


Kaplan M, Yavuz F, Kaplan G I, Bursa N, Vuruşkan E, Sucu M
Anatol J Cardiol. 2021 May; 25(5):330-337.
PMID: 33960308.


Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD.